(:BUZZ*CA)
Business Focus: N/A
Jul 28, 2021 08:51 am ET
Jul 26, 2021 10:09 am ET
CSE Bulletin: Symbol Change - Pharmadrug Inc. (BUZZ)
Toronto, Ontario--(Newsfile Corp. - Le 26 juillet/July 2021) - Pharmadrug Inc. has announced a symbol change to PHRX. Shares will begin trading under the new symbol on August 3, 2021.
Jul 23, 2021 08:00 am ET
PharmaDrug Announces Stock Ticker Symbol Change to (CSE: PHRX)
Toronto, Ontario--(Newsfile Corp. - July 23, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it will change its ticker symbol from "BUZZ" to "PHRX". The Company expects the symbol change to take effect on August 3, 2021. The change in the ticker symbol is being made to provide greater visibility with respect to the long-term strategy of the Company.
Jul 14, 2021 07:45 am ET
PharmaDrug Reports Positive Preclinical Study Results of Cepharanthine to Treat Cancers
Toronto, Ontario--(Newsfile Corp. - July 14, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce interim positive results from its ongoing preclinical study evaluating the Company's patented enteric-coated formulation of Cepharanthine ("PD-001") in a broad panel of human cancers. The study is conducted by a respected contract research organization (CRO) with deep expertise in preclinical oncology model development and drug testing.
Jul 12, 2021 05:18 pm ET
PharmaDrug Announces Change of Auditor
Toronto, Ontario--(Newsfile Corp. - July 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that MNP LLP (the "Former Auditor") has resigned as the Company's auditors, with the resignation being effective as of June 14, 2021. The Company's management and audit committee are in discussions with several auditors and will look to finalize the selection of a successor auditor in the near future.
Jun 22, 2021 07:47 am ET
PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Infectious Diseases Including COVID-19
Toronto, Ontario--(Newsfile Corp. - June 22, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has initiated preparation of a Pre-Investigational New Drug Application (pre-IND) for its patented enteric-coated formulation of cepharanthine (PD-001), an oral antiviral pill to treat mild-moderate COVID-19.
Jun 07, 2021 08:48 am ET
Pharmadrug's Supersmart Launches Psilocybin Online Retail Platform in the Netherlands
Toronto, Ontario--(Newsfile Corp. - June 7, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division has launched a Slim Winkel branded online retail platform in The Netherlands and Europe.
May 17, 2021 07:49 am ET
PharmaDrug's Super Smart Launches Online Retail Platform in the United States
Toronto, Ontario--(Newsfile Corp. - May 17, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division has launched a Slim Winkel branded online retail platform in the U.S. that will focus on functional mushrooms.
May 14, 2021 09:25 am ET
PharmaDrug Signs Supply Agreement with European Cannabis Extractor for Medical Grade THC Oil to Be Sold Under PharmaDrug Brand
Toronto, Ontario--(Newsfile Corp. - May 14, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a supply agreement (the "Supply Agreement") with an emerging Eurozone cannabis extractor for medical grade THC oil to be sold under PharmaDrug's own brand. The Company expects to receive product and begin selling in Germany by September of 2021.
May 13, 2021 08:00 am ET
PharmaDrug Enters into Employment Agreement with Dr. Paul Van Slyke and Grants Him Options and Promotes Him to Chief Scientific Officer for All of Pharmadrug
Toronto, Ontario--(Newsfile Corp. - May 13, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into an employment agreement with Dr. Paul Van Slyke and promoted him to Chief Scientific Officer (CSO) for all of PharmaDrug Inc.
May 06, 2021 09:26 am ET
PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer
Toronto, Ontario--(Newsfile Corp. - May 6, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep expertise in preclinical oncology model development and drug testing, to evaluate the Company's patented enteric-coated formulation of Cepharanthine ("PD-001") in a broad panel of human cancers.
Apr 28, 2021 08:03 am ET
PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
Toronto, Ontario--(Newsfile Corp. - April 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to dimethyltryptamine ("DMT") for prevention of ischemia-reperfusion injury ("IRI") in patients undergoing solid organ transplantation, which includes the liver, kidney, heart and lung, to the Company's wholly-owned subsidiary Sairiyo Therapeutics Inc. The FDA ODD granted is broader than the Company's original application for kidney transplantation, recognizing the pernicious consequences of IRI in all solid organ transplantation.
Apr 20, 2021 07:30 am ET
PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases
Toronto, Ontario--(Newsfile Corp. - April 20, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into an agreement with Southwest Research Institute® ("SwRI®"), to initiate non-clinical and clinical manufacturing of Cepharanthine for the Company's rare cancer and infectious diseases programs.
Mar 16, 2021 08:00 am ET
Pharmadrug Initiates DMT Research Activities via Collaboration with the University of Michigan for Foundational DMT Research Study
Toronto, Ontario--(Newsfile Corp. - March 16, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a sponsored research agreement with the University of Michigan, under the direction of Dr. Jimo Borjigin as Principal Investigator, to evaluate N, N-dimethyltryptamine's ("DMT") potential role in normal, diseased and altered states of consciousness in a newly created animal model, with the objective to develop novel therapeutic strategies of DMT for clinical unmet medical needs currently not addressed by DMT.
Mar 12, 2021 05:08 pm ET
PharmaDrug Provides Update on Its Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - March 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), will hold its Annual General Meeting ("AGM" or "Meeting") on March 25, 2021 at 10:00AM Eastern Standard Time at its corporate office, Suite 2905 - 77 King Street West, Toronto. The call-in number for the Meeting is 1-855-473-1059 and the access # 0091269.
Mar 09, 2021 08:00 am ET
PharmaDrug Announces Drug-Repurposing Expert Moshe Rogosnitzky Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 9, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") wholly-owned subsidiary, Sairiyo Therapeutics Inc. ("Sairiyo"), a biotechnology company focused on the research and development of Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases, is pleased to announce that world-renowned drug-repurposing expert, Moshe Rogosnitzky, has been appointed to Sairiyo's newly-formed scientific and clinical advisory board for Cepharanthine as a potential treatment for cancer, neurological, inflammatory and infectious diseases.
Mar 04, 2021 08:00 am ET
PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") wholly-owned subsidiary, Sariyo Therapeutics Inc. ("Sairiyo"), a biotechnology company focused on the research and development of Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases, is pleased to announce that world-renowned gastric cancer expert, Dr. Yelena Y. Janjigian, MD, has been appointed to Sairiyo's newly-formed scientific and clinical advisory board for Cepharanthine in the treatment of esophageal cancer.
Feb 25, 2021 07:33 am ET
PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney Transplantation and Expands on Its Psychedelics Strategy
Toronto, Ontario--(Newsfile Corp. - February 25, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has expanded its psychedelic pharmaceutical program with the filing of an application with the U.S. Food and Drug Administration ("FDA") to receive Orphan Drug Designation ("ODD") for N,N-Dimethyltryptamine ("DMT") in the prevention of ischemia reperfusion injury in patients undergoing kidney transplantation.
Feb 11, 2021 08:13 am ET
PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke
Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has filed an application with the U.S. Food and Drug Administration ("FDA") to receive Orphan Drug Designation ("ODD") for N,N-Dimethyltryptamine ("DMT") in the treatment of acute ischemic stroke patients presenting for emergency medical assistance within 3-hours of symptom onset.
Feb 08, 2021 07:00 am ET
PharmaDrug Appoints World-Renowned DMT Expert Dr. Steven A. Barker to Its Scientific Advisory Board for Psychedelic Pharmaceuticals
Toronto, Ontario--(Newsfile Corp. - February 8, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that is has appointed world-renowned chemist and neuroscientist Dr. Steven A. Barker, Ph.D. to the Company's newly-formed scientific advisory board for psychedelic pharmaceuticals to lead the research and development initiatives of N,N-Dimethyltryptamine ("DMT") for mental health, neurological and inflammatory disorders.
Feb 05, 2021 04:30 pm ET
PharmaDrug Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") announces the grant of stock options to directors, officers and consultants to purchase 5,200,000 common shares of the Company, exercisable at $0.085 per share at any time on or before February 4, 2026. The grants are subject to the terms of the Company's stock option plan. In accordance with regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of the grant.
Feb 04, 2021 08:23 am ET
PharmaDrug Signs Supply Agreement with Global Cannabis Supplier and Provides Update on German Operations and Balance Sheet Improvements
Toronto, Ontario--(Newsfile Corp. - February 4, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") has entered into a supply agreement (the "Supply Agreement") on January 4, 2021, with a Canadian based multinational cannabis company for EU-GMP certified medical cannabis. The supply is already registered and approved for sale in the German market.
Feb 02, 2021 08:39 am ET
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
Toronto, Ontario--(Newsfile Corp. - February 2, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has completed the previously announced (see press releases dated January 12, 2021 and January 25, 2021) acquisition of Sairiyo Therapeutics Inc. ("Sairiyo") on February 2, 2021.
Jan 25, 2021 08:19 am ET
PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer
Toronto, Ontario--(Newsfile Corp. - January 25, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has entered into the definitive agreement in respect of the previously announced (see press release dated January 12, 2021) proposed acquisition of Sairiyo Therapeutics Inc. ("Sairiyo") on January 12, 2021. Management of the Company believe that the proposed acquisition will strengthen PharmaDrug's product pipeline, intellectual property portfolio and pharmaceutical development expertise.
Jan 12, 2021 08:32 am ET
IIROC Trade Resumption - BUZZ
VANCOUVER, BC, Jan. 12, 2021 /CNW/ - Trading resumes in:
Jan 12, 2021 08:00 am ET
PharmaDrug Announces LOI to Acquire Sairiyo Therapeutics Inc.
Toronto, Ontario--(Newsfile Corp. - January 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a binding letter of intent (the "LOI"), dated January 11, 2021, to acquire Sairiyo Therapeutics Inc. ("Sairiyo") (the "Acquisition").
Jan 11, 2021 02:10 pm ET
IIROC Trading Halt - BUZZ
VANCOUVER, BC, Jan. 11, 2021 /CNW/ - The following issues have been halted by IIROC:
Dec 15, 2020 08:38 am ET
Pharmadrug Provides Corporate Update and Balance Sheet Status
Toronto, Ontario--(Newsfile Corp. - December 15, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to provide an update to the status of its balance sheet following the recent general equity market upswing and the increase in PharmaDrug's volume and share price appreciation.
Nov 30, 2020 09:08 am ET
Pharmadrug Shortlists Prime Amsterdam Locations for State-of-the-art Smart Shop Superstore and Expands Scope of E-Commerce Platform with Essential Good
Toronto, Ontario--(Newsfile Corp. - November 30, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) ("Super Smart") will be launching its new Slim Winkel brand in the next couple of weeks. The Company's work with Essential Good LLC ("Essential Good") has advanced tremendously and the Company expects the new online retail store will be ready to launch early in the new year with differentiated brand positioning and an enhanced product line. The company has also narrowed its search for an Amsterdam location where Super Smart plans to build a major flagship superstore for its new retail concept.
Nov 23, 2020 08:31 am ET
PharmaDrug Positions for Eurozone Psychedelic Distribution as Germany Begins Psilocybin Depression Study
Toronto, Ontario--(Newsfile Corp. - November 23, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") applauds the recent approval by Germany's Federal Institute of Drugs and Medical Devices (BfArM) of a study examining the Efficacy and Safety of Psilocybin in Treatment-Resistant Depression. This marks the first psilocybin depression study in Germany since the 1970s and serves to further demonstrate the broadening acceptance towards the potential use of psychedelics to treat various ailments. The study will be funded by the German Government. The study will start recruiting patients in January and begin treating patients by March of 2021.
Oct 13, 2020 07:38 am ET
PharmaDrug's Super Smart Begins to Work with Essential Good to Develop Its Brand and Build an Innovative Online Retail Platform
Toronto, Ontario--(Newsfile Corp. - October 13, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) ("Super Smart") has begun to work with Essential Good LLC ("Essential Good") to develop its Slim Winkel brand and establish an online retail platform that will focus on functional mushrooms and other legal medical plants and that within The Netherlands will include the sale of psilocybin truffles.
Sep 28, 2020 08:00 am ET
PharmaDrug's Super Smart Reaches Distribution Agreement with Red Light Holland for iMicrodose Packs and for Red Light Holland to Build out an iMicrodose Media Information Centre (iMIC) with Super Smar
Toronto, Ontario--(Newsfile Corp. - September 28, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC PINK: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) ("Super Smart") has reached a distribution agreement with Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC:TRUFF) (Red Light Holland") for Red Light Holland's iMicrodose Packs ("iMicrodose Packs"). The iMicrodose Packs are expected to be available in Super Smart's first Slim Winkel store, located in Tiel, in early October 2020.
Sep 21, 2020 09:02 am ET
Pharmadrug Inc. Closes Transaction to Acquire First Smart Shop in the Netherlands and Now Initiates Major Push to Acquire Best of Breed High Traffic Locations
Toronto, Ontario--(Newsfile Corp. - September 21, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) ("Super Smart") has closed the transaction to acquire the retail establishment specializing in the sale of psychedelic products that was previously announced in the Definitive Agreement signed on August 14, 2020.
Sep 01, 2020 08:54 am ET
Pharmadrug Enters into Employment Agreements with Executive Team and Grants Stock Options and Also Provides Update on Super Smart Store Acquisition
Toronto, Ontario--(Newsfile Corp. - September 1, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that it has entered into employment agreements with Daniel Cohen, the Company's Chairman and CEO, and Harry Resin, President of PharmaDrug's wholly-owned subsidiary Interrobang Ltd. d/b/a Super Smart. The Company has also granted incentive options to its Board of Directors and Officers and issued share-based compensation to 7725434 Canada Inc. (a holding company controlled by Daniel Cohen), and Howard Brass, the Company's former chief operating officer, to settle unpaid amounts owing under previous consulting agreements. Daniel Cohen has not been earning a salary since October of 2019.
Aug 11, 2020 07:00 am ET
PharmaDrug Inc. Enters into Definitive Agreement to Acquire First Smart Shop in the Netherlands
Toronto, Ontario--(Newsfile Corp. - August 11, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) ("Super Smart") has entered into a definitive agreement to acquire (the "Acquisition") a retail establishment specializing in the sale of psychedelic products (the "Target Smart Shop").
Jul 22, 2020 08:28 am ET
Pharmadrug Inc. Signs Cannabis Supply Agreement with Eve & Co
Toronto, Ontario--(Newsfile Corp. - July 22, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that it has entered into a supply agreement (the "Supply Agreement") with Natural MedCo Ltd.("NMC"), a Canadian Licensed Producer of medical cannabis and a wholly-owned subsidiary of Eve & Co Incorporated ("Eve & Co") (TSXV: EVE) (OTCQX: EEVVF) for bulk and finished EU-GMP medical cannabis.
Jul 17, 2020 05:48 pm ET
PharmaDrug Inc. Repays Amounts Owing Under Bridge Loan and Advisory Agreement, Completes Previously Announced Debt Restructuring and Provides Financial Update
Toronto, Ontario--(Newsfile Corp. - July 17, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that it has repaid amounts owing by the Company to the lender (inclusive of interest and fees) pursuant to a bridge loan (the "Bridge Loan") and amounts owing to a financial advisor under an advisory agreement (the "Advisory Fee").
Jul 16, 2020 08:33 am ET
Pharmadrug Inc. Completes Strategic Mutual Investment with Red Light Holland Corp.
Toronto, Ontario--(Newsfile Corp. - July 16, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that it has completed the share exchange transasction with Red Light Holland Corp. ("RLH") (CSE: TRIP) (FSE: 4YX), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, announced in the Company's July 16, 2020 press release.
Jul 16, 2020 08:30 am ET
Red Light Holland Announces Closing of Final Tranche of Fully Subscribed Private Placement Including Strategic Mutual Investment with PharmaDrug
Toronto, Ontario--(Newsfile Corp. - July 16, 2020) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) ("Red Light Holland" or the "Company"), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has closed the final tranche (the "Final Tranche") of its previously announced and now fully subscribed private placement (the "Private Placement") of units (the "RLH Units").
Jul 15, 2020 09:14 am ET
PharmaDrug Inc. Proposes a Strategic Mutual Investment with Red Light Holland Corp.
Toronto, Ontario--(Newsfile Corp. - July 15, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that it has entered into a share exchange agreement with Red Light Holland Corp. (CSE: TRIP) ("RLH"), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands.
Jul 15, 2020 09:14 am ET
Red Light Holland Announces Strategic Mutual Investment with PharmaDrug
Toronto, Ontario--(Newsfile Corp. - July 15, 2020) - Red Light Holland Corp. (CSE: TRIP) (FSE:4YX) ("Red Light Holland" or the "Company"), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has entered into a securities exchange agreement dated July 14, 2020 (the "Securities Exchange Agreement") with PharmaDrug Inc. (CSE: BUZZ) ("PharmaDrug").
Jul 09, 2020 08:44 am ET
Pharmadrug Inc. Provides Update on Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - July 9, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that further to its press release dated May 20, 2020, that it proposes to complete a restructuring of certain of its outstanding indebtedness.
Jun 29, 2020 04:56 pm ET
Pharmadrug Inc. Announces Postponement of Executive Compensation Disclosure
Toronto, Ontario--(Newsfile Corp. - June 29, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") announced that it will be relying on the temporary blanket relief provided by the Canadian Securities Administrators to postpone filing of its executive compensation disclosure required under applicable securities laws until such time until such time as it is filed and delivered to shareholders as part of the Company's management information circular relating to its 2020 annual meeting of shareholders.
Jun 19, 2020 07:00 am ET
Top Canadian Entreprenuer Michael Forbes Joins the Board of Directors of PharmaDrug Inc.
Toronto, Ontario--(Newsfile Corp. - June 19, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that Michael Forbes will be joining the board effective immediately.
Jun 15, 2020 11:26 am ET
IIROC Trade Resumption - BUZZ
VANCOUVER, BC, June 15, 2020 /CNW/ - Trading resumes in:
Jun 15, 2020 09:20 am ET
Pharmadrug Inc. Completes Acquisition of Super Smart with a New Added Focus on the Psychedelic Market
Toronto, Ontario--(Newsfile Corp. - June 15, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("Pharmadrug" or the "Company") is pleased to announce that it has completed its previously announced (see press release dated May 25, 2020) acquisition of all of the issued and outstanding shares of privately-held Interrobang Ltd. (doing business as Super Smart). ("Super Smart"). The acquisition was completed by way of a three-cornered amalgamation between Pharmadrug, Super Smart and a wholly-owned subsidiary of Pharmadrug (the "Transaction"). Following completion of the Transaction Super Smart is a wholly-owned subsidiary of Pharmadrug.
Jun 15, 2020 08:50 am ET
IIROC Trading Halt - BUZZ
VANCOUVER, BC, June 15, 2020 /CNW/ - The following issues have been halted by IIROC:
Jun 10, 2020 11:39 am ET
PharmaDrug Receives Conditional Approval for Grant of Options
Toronto, Ontario--(Newsfile Corp. - June 10, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "PharmaDrug") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange for the previously announced (see press release dated June 2, 2020) grant of 5,000,000 options (the "Options") to Terry Booth.
Jun 08, 2020 06:09 pm ET
PharmaDrug Announces Application for Management Cease Trade Order
Toronto, Ontario--(Newsfile Corp. - June 8, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "PharmaDrug") announced today that it has made an application to the Ontario Securities Commission to approve a temporary management cease trade order ("MCTO") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), which, if granted, will prohibit trading in securities of the Company by its Chief Executive Officer, Chief Financial Officer and certain other insiders of the Company, whether direct or indirect, so long as the 2019 Filings (as defined below) remain outstanding. The issuance of an MCTO would generally not affect the ability of persons who are not, or who have not been, directors, officers or other insiders of the Company to trade in the Company's securities.
Jun 03, 2020 04:30 pm ET
PharmaDrug Provides Update on Annual and Interim Financial Statements
Toronto, Ontario--(Newsfile Corp. - June 3, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "PharmaDrug") announces, further to its April 24, 2020 news release in relation to the timing of the filing of its year-end financial statements, the Company still expects to file such documents on or prior to June 15, 2020.
Jun 02, 2020 09:44 am ET
IIROC Trade Resumption - BUZZ
VANCOUVER, BC, June 2, 2020 /CNW/ - Trading resumes in:
Jun 02, 2020 08:35 am ET
Pharmadrug Appoints Cannabis Icon Terry Booth as Chairman of Advisory Board
Toronto, Ontario--(Newsfile Corp. - June 2, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "PharmaDrug") is pleased to announce that it has appointed global cannabis industry pioneer and founder of Aurora Cannabis Inc. (NYSE: ACB) ("Aurora"), Terry Booth, as the Chairman of its advisory board focussing on the Company's psychedelic business.
Jun 01, 2020 10:07 am ET
IIROC Trading Halt - BUZZ
VANCOUVER, June 1, 2020 /CNW/ - The following issues have been halted by IIROC:
May 29, 2020 08:56 am ET
Pharmadrug Inc. Unveils Roadmap for European Psilocybin Business
Toronto, Ontario--(Newsfile Corp. - May 29, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") has released an overview of their plans to enter the European psilocybin marketplace via the pending closing of the acquisition of Interrobang LTD. currently doing business as Super Smart (herein referred to as "Super Smart"). The Company intends to utilize a unique two-prong approach, capitalizing on markets in The Netherlands through "smart shop" consolidation and the entire European Union by way of PharmaDrug's controlled substance important and distribution license.
May 25, 2020 04:55 pm ET
Pharmadrug Inc. Enters into Unsecured Promissory Note
Toronto, Ontario--(Newsfile Corp. - May 25, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("Pharmadrug" or the "Company") announced today that it has issued a non-interest bearing unsecured promissory note to privately-held Interrobang Ltd. (doing business as Super Smart) ("Super Smart") pursuant to which Super Smart will loan the Company $80,000 payable on August 25, 2020.
May 25, 2020 08:53 am ET
Pharmadrug Inc. Enters Definitive Agreement to Acquire Super Smart Paving Its Entry into the Psychedelic Market
Toronto, Ontario--(Newsfile Corp. - May 25, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("Pharmadrug" or the "Company") is pleased to announce that it has entered into a definitive agreement (the "Acquisition Agreement") pursuant to which Pharmadrug will acquire all of the issued and outstanding shares of privately-held Interrobang Ltd. (doing business as Super Smart). ("Super Smart"), to be effected by way of a three-cornered amalgamation between Pharmadrug, Super Smart and a wholly-owned subsidiary of Pharmadrug (the "Proposed Transaction"). Following completion of the Proposed Transaction Super Smart will become a wholly-owned subsidiary of Pharmadrug. It is anticipated that the Proposed Transaction will be completed in early June, 2020.
May 20, 2020 11:04 am ET
IIROC Trade Resumption - BUZZ
VANCOUVER, May 20, 2020 /CNW/ - Trading resumes in:
May 20, 2020 10:37 am ET
Pharmadrug Inc. Plans to Enter the Psychedelic Space with An LOI To Acquire Super Smart and Provides Business Update
Toronto, Ontario--(Newsfile Corp. - May 20, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("Pharmadrug" or the "Company") is pleased to announce that it has entered into a non-binding letter of intent (the "Letter of Intent") dated May 20, 2020 with Interrobang Ltd. doing business as Super Smart (herein referred to as "Super Smart") which outlines the general terms and conditions of a proposed transaction (the "Proposed Transaction") that will result in Pharmadrug acquiring all of the issued and outstanding common shares (the "Super Smart Shares") and other securities of Super Smart.
May 15, 2020 02:00 pm ET
IIROC Trading Halt - BUZZ
VANCOUVER, May 15, 2020 /CNW/ - The following issues have been halted by IIROC:
Apr 24, 2020 08:00 am ET
Pharmadrug Inc. Provides Update on COVID-19 and Announces Request for Extension of Filing Financial Statements as Well as Positive Business and Corporate Updates
Toronto, Ontario--(Newsfile Corp. - April 24, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company") is providing an update on COVID-19 matters and an update on the status of filing its financial statements and accompanying management's discussion and analysis, and related CEO and CFO certifications for the financial year ended December 31, 2019.
Feb 07, 2020 08:36 am ET
Pharmadrug Inc. Enters Secured Loan Agreement and LOI for Possible Business Combination
Toronto, Ontario--(Newsfile Corp. - February 7, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company") is pleased to announce that it has secured a private loan (the "Loan") of $250,000 from an arm's length third party lender (the "Lender"). The Loan carries an interest rate of 9% per annum accruing every 90 days, payable on maturity with such interest increasing to 15% per annum from the date of the occurrence of an event of default. The Loan is secured by general security agreements from the Company and its material subsidiaries, a pledge of shares by the Company of its interest in Pharmadrug GmbH and guarantees from the Company's material subsidiaries.
Nov 29, 2019 08:37 am ET
Pharmadrug Announces Q3 2019 Financial Results
Toronto, Ontario--(Newsfile Corp. - November 29, 2019) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Pharmadrug"), a leading European medical cannabis distribution company, today announced its financial results for the third quarter ending September 30, 2019. The Company's full Management's Discussion and Analysis ("MD&A") is available on SEDAR (www.sedar.com).
Nov 19, 2019 07:00 am ET
Israeli Government in Discussions on Medical Cannabis Export Framework & Appointment of New Board Member
Toronto, Ontario--(Newsfile Corp. - November 19, 2019) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Pharmadrug") would like to update investors on developments from Israel's Ministry of Health regarding the export law on medical cannabis passed in January of 2019 (the "Export Law"). It was revealed late last week that the Israeli Ministry of Health (the "Ministry") will soon be publishing its cannabis export guidelines, which will enable the commencement of exports to international markets, most notably Germany and other European Countries. In a statement to the Israeli High Court, the Ministry said, "For the Ministry of Health, any business that meets the standard for local production and marketing will be able market its products abroad." As a reminder (see press release dated September 19, 2019), Pharmadrug has signed a multi-year supply agreement with My Greenfields, a nursery and cultivation license holder in Israel. Under the terms of the agreement, My Greenfields will provide Pharmadrug with up to 2,000 kg of medical cannabis per annum for the German and European markets.
Oct 31, 2019 11:58 am ET
Pharmadrug Signs Major Canadian Supply Agreement with Canada House Wellness for German Distribution as German Governing Party Moves Closer to Recreational Cannabis Legislation
Toronto, Ontario--(Newsfile Corp. - October 31, 2019) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Pharmadrug") is pleased to announce a multi-year supply agreement (the "Supply Agreement") between 80% owned subsidiary Pharmadrug Production GmbH and Canada House Wellness Group Inc. (CSE: CHV) (the "Grower" or "Canada House").
Oct 21, 2019 08:04 am ET
Aura Health Announces Name Change to Pharmadrug to Reflect Focus on Pharmaceutical Medicine
Toronto, Ontario--(Newsfile Corp. - October 21, 2019) - Aura Health Inc. ("Aura") (CSE:BUZZ) (OTC: LMLLF) is pleased to announce that it has completed its name change from Aura Health Inc. to Pharmadrug Inc. ("Pharmadrug" or the "Company") (the "Name Change"). Aura's shareholders approved the name change at the annual and special meeting of shareholders held on October 3, 2019.
Oct 03, 2019 08:31 am ET
Aura Announces Extension of Maturity and Partial Repayment of Bridge Loan Facility
Toronto, Ontario--(Newsfile Corp. - October 3, 2019) - Aura Health Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Aura") is pleased to announce that the CAD$3 million bridge loan facility (the "Bridge Loan Facility") entered into by the Company and a private lender (the "Lender") on May 8, 2019, has been amended to mature in six months on March 24, 2020 (the "Maturity Date"). The outstanding principal and accrued interest on the Bridge Loan Facility shall be due and payable in full by the Company on the Maturity Date. The Company is entitled to prepay all or any part of the Bridge Loan Facility at any time and from time to time.
Sep 19, 2019 09:40 am ET
Aura's Pharmadrug Signs Major Supply Agreement Setting Stage for Brand Launch & Expanded Distribution
Toronto, Ontario--(Newsfile Corp. - September 19, 2019) - Aura Health Inc. (CSE:BUZZ) (OTC:LMLLF) (the "Company" or "Aura") is pleased to announce a multi-year supply agreement (the "Supply Agreement") between 80% owned subsidiary Pharmadrug Production GmbH ("Pharmadrug") and Israel-based My Green Fields Ltd. ("My Green Fields" or the "Grower").
Aug 13, 2019 08:23 am ET
Aura Announces Pharmadrug Operational & Investor Relations Update
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF) is pleased to provide an operational update on Pharmadrug Production GmbH (the “German Business” or “Pharmadrug”) and additional resources allocated to investor relations....
Jul 31, 2019 07:07 am ET
Jun 14, 2019 08:00 am ET
Aura Signs Master Grower for Israel
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce the signing of master grower, Adrian Richelmi, to build and operate HolyCanna’s 60,000 square foot greenhouse facilty in Israel. Aura is a debt holder of HolyCanna that...
Jun 07, 2019 04:15 pm ET
Aura Provides Clarification on Pharmadrug’s Supply Agreements and Relationship With Bedrocan
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) wishes to clarify the nature of the supply arrangement by which Pharmadrug Production GmbH (“Pharmadrug”) is importing and distributing cannabis to pharmacies in Germany. In a press release...
Jun 05, 2019 08:46 am ET
Aura Provides Update on Pharmadrug and Its European Strategy
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to provide an update on its operations and corporate strategy regarding the German medical cannabis market. As announced on May 17, 2019, the Company closed its acquisition of 80% of...
May 31, 2019 08:10 am ET
Aura Announces Appointment of Al Quong to Its Board of Directors
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce the appointment of Al Quong to its board of directors, subject to regulatory approval. Mr. Quong is an experienced finance professional, with more than 25 years of...
May 24, 2019 08:56 am ET
Aura Initiates Investor Relations Strategy
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has engaged two firms to assist with an investor relations strategy for the Company. Adelaide Capital Markets (“Adelaide”) and CanaCom Group, the parent company of...
May 17, 2019 11:19 am ET
Aura Announces Strategic Entry Into the European Market With the Closing of the Acquisition of Pharmadrug
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has closed the previously announced (May 8, 2019) acquisition of an 80% equity interest in Pharmadrug Production GmbH (“Pharmadrug”) for total consideration of...
May 08, 2019 09:15 am ET
Aura Announces Supply Agreement With FSD Pharma & Conditions Met to Close German Acquisition
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce a multi-year supply agreement with FSD Pharma Inc. (“FSD”) and that milestones have been met to allow the Company to close the acquisition of an 80% equity interest in...
May 01, 2019 03:21 pm ET
Aura Signs Definitive Agreement Disposing of U.S. Cannabis Certification Clinics
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that its wholly owned subsidiary, Green Global Properties Inc. (“GGPI”), has entered into a definitive purchase and sale agreement dated April 30, 2019 (the “PSA”) with...
Apr 17, 2019 03:29 pm ET
Aura Health Announces $5.82 Million Closing of the Second Tranche of Its Subscription Receipt Offering and Share Exchange Transaction
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has closed the second tranche of its previously announced “best efforts” private placement subscription receipt offering (the “Offering”) for additional gross...
Mar 26, 2019 08:00 am ET
Aura Announces Appointment of Alain Dobkin to its Board of Directors
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce the appointment of Alain Dobkin to its board of directors, subject to regulatory approval. Alain is a private equity investor with more than 20 years of investment and...
Feb 28, 2019 09:13 am ET
Aura Announces Signing of Definitive Share Purchase Agreement to Acquire Licenced Medical Cannabis Distributor in Germany
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that the Company has entered into a definitive share purchase agreement dated February 27, 2019 (the “SPA”) to acquire an 80% equity interest in Pharmadrug Production GmbH...
Feb 27, 2019 01:42 pm ET
Aura Health Announces Closing of $1.9 Million on the First Tranche of Subscription Receipt Financing
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has closed the first tranche (the “First Tranche Closing”) of its previously announced “best efforts” private placement subscription receipt offering (the...
Feb 22, 2019 11:01 am ET
Aura Health Provides Further Clarity Regarding Offering and Strategic Investor
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to provide further clarity on the press release dated February 21, 2019 with regards to the upsized private placement subscription receipt offering (the “Offering”), including the...
Feb 21, 2019 08:19 am ET
With a Strategic Investment by Aleafia Health, Aura Health Announces Increase to Previously Announced Brokered Subscription Receipt Financing to $7.26 Million
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that, due to investor demand, the Company has increased the size of its previously announced private placement subscription receipt offering (the “Offering”) to a maximum...
Feb 08, 2019 08:09 am ET
Aura Health Announces Pricing of Previously Announced $5.0 Million Brokered Subscription Receipt Financing
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce the price and terms of its brokered private placement subscription receipt offering previously announced on February 4, 2019 (the “Offering”), led by Mackie Research...
Feb 04, 2019 08:23 am ET
Aura Health Announces $5 Million Brokered Subscription Receipt Financing
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has engaged Mackie Research Capital Corporation (the “Lead Agent”) to act as lead agent and sole book runner, along with Haywood Securities Inc., PI Financial...
Jan 28, 2019 08:00 am ET
Israel Passes Cannabis Export Law, Paving Path for Aura’s European Distribution
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased with the final approval of Israel’s export law for medical cannabis. On Sunday, January 27, the Israeli government announced the new law, approving the export of Israeli-grown...
Jan 25, 2019 10:57 am ET
Aura Announces Binding LOI to Acquire Licenced Medical Cannabis Distributor in Germany
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that the Company has entered into a binding letter of intent (the “LOI”) to acquire 80% of Pharmadrug Production GmbH (“Pharmadrug”) for EUR5,000,000. Pharmadrug is a...
Jan 25, 2019 10:26 am ET
IIROC Trade Resumption - BUZZ
VANCOUVER, Jan. 25, 2019 /CNW/ - Trading resumes in:
Jan 24, 2019 11:03 am ET
IIROC Trading Halt - BUZZ
VANCOUVER, Jan. 24, 2019 /CNW/ - The following issues have been halted by IIROC:
Jan 18, 2019 08:00 am ET
Aura Enters PR Campaign in Western Canada & Grants Options to Director
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce that the Company has entered into a strategic PR campaign in Western Canada with R. Ian Cochrane. Mr. Cochrane brings three decades of marketing small and microcap...
Jan 11, 2019 08:00 am ET
Aura Announces Closing of Non-Brokered Private Placement
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce that on January 10, 2019 (the “Closing Date”) it closed its previously announced non-brokered private placement raising gross proceeds of $1,724,099.85 (the “Offering”)....
Jan 08, 2019 08:13 am ET
Aura Announces Upsizing of Non-Brokered Private Placement
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce that due to increased demand it has upsized its previously announced non-brokered private placement (see press release dated January 7, 2019) from $1,500,000 to up to...
Jan 07, 2019 08:19 am ET
Aura Announces Non-Brokered Private Placement of Up to $1,500,000
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce that it is raising up to $1,500,000 by way of a non-brokered private placement of units of the Company (each a “Unit” and collectively, the “Units”) at a price of $0.15...
Nov 23, 2018 08:12 am ET
Aura Closes Strategic Investment Into HolyCanna, Bolstering International Strategy
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce the closing of its previously announced letter of intent (“LOI”) to secure a majority (54%) equity stake in HolyCanna Ltd. (“HolyCanna”), an Israel-based company with a...
Nov 19, 2018 08:00 am ET
Aura Announces Appointment of New Chief Operating Officer and Board Approval of Stock-Based Compensation Plan
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce the appointment of Howard Brass to the role of Chief Operating Officer, effective immediately. Mr. Brass has nearly a decade of capital markets experience and spent...
Oct 29, 2018 08:21 am ET
Aura Closes $400,000 Convertible Debenture Offering
Aura Health Inc. (the "Company" or “Aura”) (CSE: BUZZ) is very pleased to announce that it has closed a non-brokered private placement offering (the “Offering”) on October 26th, 2018 (“Closing Date”) of unsecured convertible debentures bearing...
Oct 17, 2018 08:27 am ET
Nutritional High and Aura Health Announce Partnership to Develop International Markets
Nutritional High International Inc. ("Nutritional High") (CSE: EAT, OTCQB: SPLIF, FRANKFURT:2NU) and Aura Health Inc. (“Aura”) (CSE: BUZZ) are pleased to announce the development of a framework to bring Nutritional High’s extraction and edibles...
Oct 03, 2018 09:58 am ET
Aura Appoints New Director
Aura Health Inc. (the “Company” or “Aura”) (CSE: BUZZ) wishes to announce the following changes to its board of directors (the “Board”). Effective immediately, Joel Freudman has been appointed to the Board as an independent director and Chair of...
Sep 24, 2018 08:00 am ET
Aura Enters into Investor Relations Contract with First Canadian Capital Corp. and Issues Options to CEO and Consultants
Aura Health Inc. (the "Company" or “Aura”) (CSE: BUZZ) is pleased to announce it has entered into an Investor Relations Agreement (the “Agreement”) to have First Canadian Capital Corp. (“First Canadian”) provide Investor Relations services to Aura...
Sep 05, 2018 08:33 am ET
Aura to Acquire Majority Interest in Israeli Cannabis Retailer in Partnership With Industry Icon Shlomi Sendak
Aura Health Inc. (the "Company" or “Aura”) (CSE: BUZZ) is very pleased to announce it has entered into a binding term sheet (“Term Sheet” or “Agreement”) to acquire 57% of the outstanding equity of CannabiSendak LTD. (“CannabiSendak”), an Israeli...
Aug 22, 2018 08:00 am ET
Aura Enters Into Agreement to Acquire Majority Interest in Israeli Cannabis Company
Aura Health Inc. (the "Company" or “Aura”) (CSE: BUZZ) is very pleased to announce it has entered into a binding letter of intent (“LOI”) to subscribe to an unsecured convertible note (“Convertible Note”) in Holycanna Ltd. (“Holycanna”), an...
Aug 17, 2018 09:10 am ET
CSE New Listing - Aura Health Inc. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2018) - Aura Health Inc. (CSE:BUZZ) is the latest new listing on the Canadian Securities Exchange, following a reverse take over with Lamêlée Iron Ore, which previously traded on the TSX Venture Exchange. Aura is engaged in the identification, acquisition and management of a portfolio of investments in Marijuana Service Businesses, which are not involved in cultivating or processing of marijuana products, but rather provide a service within a regulated jurisdiction.
Aug 16, 2018 09:23 am ET
Aura announces appointment of new chief executive officer
Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is very pleased to announce the appointment of Daniel Cohen to the role of Chief Executive Officer (CEO), effective immediately. Former CEO Chris Carl will continue to serve in his role as...
Aug 16, 2018 08:57 am ET
Nutritional High Congratulates Aura Health on Its Commencing Trading on the CSE
Nutritional High International Inc. (the “Company” or “Nutritional High”) (CSE: EAT, OTCQB: SPLIF, FRANKFURT: 2NU) would like to congratulate Aura Health Inc. (“Aura”) (CSE: BUZZ) for their listing approval and commencement of trading on Thursday,...
Aug 10, 2018 05:25 pm ET
Aura Health Announces Closing of RTO Transaction
Aura Health Inc. (the "Corporation"), formerly Lamêlée Iron Ore Ltd., is pleased to announce that it completed on August 9, 2018 its previously announced reverse take-over transaction (the "RTO Transaction") with Aura Health Corp. ("Aura"). Aura is...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.